AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
BriaCell Therapeutics Trading Halted: News Pending
ByAinvest
Saturday, Aug 23, 2025 9:42 am ET1min read
BriaCell Therapeutics' stock trading has been halted pending news. Elevate your investing strategy with TipRanks Premium at 50% off, unlocking powerful tools, advanced data, and expert insights.
BriaCell Therapeutics Corp. (BCT), a clinical-stage biotechnology company specializing in novel immunotherapies for cancer care, has seen its stock trading halted by the TSX pending news. The company's lead candidate, Bria-IMT, is a patented, off-the-shelf, cell-based immunotherapy that activates the patient's immune system to specifically kill cancer cells without harming other cells. Bria-IMT is currently being tested in combination with an immune checkpoint inhibitor in a pivotal Phase 3 study for metastatic breast cancer [1].The stock has experienced volatility in recent months, with both positive and negative price movements. For instance, on April 21, 2023, BriaCell Therapeutics' stock was up on the Toronto Stock Exchange, but it was down on August 17, 2023. The company has also received significant attention from investors and analysts, with some predicting substantial growth potential. For example, H.C. Wainwright initiated a buy rating for the stock, citing the company's promising pipeline and potential for significant market impact [2].
BriaCell Therapeutics has also been active in securing partnerships and grants to advance its research. In September 2023, the company announced a collaboration with Caris Life Sciences to expand patient outreach and molecular profiling. Additionally, it has been presenting its clinical data at major conferences such as the Society for Immunotherapy of Cancer (SITC) Annual Meeting and the American Association for Cancer Research (AACR) Annual Meeting [1].
Despite the recent trading halt, BriaCell Therapeutics continues to make progress in its mission to transform cancer care through innovative immunotherapy solutions. Investors should closely monitor the upcoming news that will likely influence the stock's trading status.
References:
[1] https://www.marketscreener.com/news/briacell-therapeutics-announces-1-for-10-share-consolidation-ce7c50dad98afe20
[2] https://www.marketbeat.com/stocks/CVE/BCT/news/
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet